Matei-Man, A.-M.; Gaal, I.-O.; Catana, A.; Vesa, S.; Senila, S.; Candrea, E.; Orasan, M.; Puskas, A.; Man, A.C.; Mocan, T.
IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort. Medicina 2026, 62, 1041.
https://doi.org/10.3390/medicina62061041
AMA Style
Matei-Man A-M, Gaal I-O, Catana A, Vesa S, Senila S, Candrea E, Orasan M, Puskas A, Man AC, Mocan T.
IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort. Medicina. 2026; 62(6):1041.
https://doi.org/10.3390/medicina62061041
Chicago/Turabian Style
Matei-Man, Alessandra-Madalina, Ildiko-Orsolya Gaal, Andreea Catana, Stefan Vesa, Simona Senila, Elisabeta Candrea, Meda Orasan, Alexandra Puskas, Ana Calina Man, and Teodora Mocan.
2026. "IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort" Medicina 62, no. 6: 1041.
https://doi.org/10.3390/medicina62061041
APA Style
Matei-Man, A.-M., Gaal, I.-O., Catana, A., Vesa, S., Senila, S., Candrea, E., Orasan, M., Puskas, A., Man, A. C., & Mocan, T.
(2026). IL12B rs3213094 as a Predictor of Early Response to Biologic Therapy in Psoriasis: A Real-World Study in a Romanian Cohort. Medicina, 62(6), 1041.
https://doi.org/10.3390/medicina62061041
